grn-300
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 21, 2020 (NCT04711161)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase SIK2INHIBITOR
SIK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04711161 | Phase 1 | Dec 21, 2020 | Green3Bio, Inc., University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green3Bio, Inc. | For profit | 1 | 1 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1